Financial Analysis: InflaRx (LUMO) & Its Rivals
InflaRx (NASDAQ: LUMO) is one of 611 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare InflaRx to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.
This is a summary of recent ratings and target prices for InflaRx and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares InflaRx and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|InflaRx Competitors||$2.13 billion||$268.21 million||0.01|
InflaRx’s rivals have higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
InflaRx has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, InflaRx’s rivals have a beta of 1.60, suggesting that their average stock price is 60% more volatile than the S&P 500.
This table compares InflaRx and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
45.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 12.7% of InflaRx shares are held by company insiders. Comparatively, 15.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
InflaRx rivals beat InflaRx on 10 of the 13 factors compared.
InflaRx Company Profile
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.